- Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfrontPlus news on Alchemab, Scipher and Forte. 💉 Ipsen’s Dysport aces Phase 3 migraine trials: The biotech’s injectable neurotoxin met the primary endpoint of reducing monthly migraine days in two ...Endpoints · 16d ago↗ source
- STAT+: Prime wins Beam arbitration, clearing path to clinicAstraZeneca, Ionis report major trial failure, White House pushes for American drug manufacturing, and more biotech news from The ReadoutSTAT · 16d ago↗ source
- Eli Lilly dominates first-half biotech acquisitions, with no sign of slowing downRiding on its trillion-dollar heft and successes in treating obesity, Eli Lilly has now become a force in one area where it hasn’t historically been the main player: M&A. The Indianapolis-bas…